Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Core Insights - The chemical pharmaceutical sector experienced a rise of 0.48% on August 22, with Duori Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Stock Performance - Duori Pharmaceutical (301075) closed at 45.48, with an increase of 8.54% and a trading volume of 98,000 shares, amounting to a transaction value of 426 million [1] - Maiwei Biological (688062) saw a closing price of 39.22, up 7.10%, with a trading volume of 194,300 shares, totaling 749 million [1] - Lifan Pharmaceutical (003020) closed at 38.48, increasing by 6.68%, with a trading volume of 153,200 shares, resulting in a transaction value of 584 million [1] - Other notable performers included Tonghua Jinma (000766) with a 6.03% increase and Qianhong Pharmaceutical (002550) with a 5.52% increase [1] Fund Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 1.428 billion from institutional investors, while retail investors contributed a net inflow of 1.492 billion [2] - The table of fund flows indicates that Qianhong Pharmaceutical (002550) had a net inflow of 157 million from institutional investors, while it experienced a net outflow of 44.058 million from speculative funds [3] - Other companies like Lijun Group (000513) and Xianju Pharmaceutical (002332) also showed varying net inflows and outflows from different investor categories [3]

Group 1 - The latest stock price of Duori Pharmaceutical is 37.76 yuan, an increase of 0.85 yuan from the previous trading day, with a highest intraday price of 38.07 yuan and a lowest of 36.37 yuan [1] - The company operates in the chemical pharmaceutical industry, focusing on the research and production of pharmaceutical products, including chemical drugs and traditional Chinese medicine [1] - The product line includes Yifei Jisheng granules, which is a Class 1 new traditional Chinese medicine currently undergoing Phase II clinical trials [1] Group 2 - Duori Pharmaceutical stated on the investor interaction platform that the research and development of Yifei Jisheng granules is progressing as planned, emphasizing the long cycle and high uncertainty associated with pharmaceutical R&D [1] - The net outflow of main funds on the day was 2.0484 million yuan, with a cumulative net outflow of 23.9297 million yuan over the past five trading days [1]

证券代码：301075 证券简称：多瑞医药 公告编号：2025-064 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起12 个月内，在上述使用期限及额度范围内，资金可循环滚动使用。在额 度范围内授权公司法定代表人及其授权人士签署相关合同文件，授权 期限自董事会审议通过之日起 12 个月内有效。该事项已经公司董事 会、监事会审议通过，保荐机构中信证券股份有限公司对公司使用部 分暂时闲置募集资金进行现金管理出具了明确的核查意见。具体内容 详见于巨潮资讯网（www.cninfo.c ...

天眼查商业履历信息显示，西藏多瑞医药股份有限公司，成立于2016年，位于昌都市，是一家以从事批 发业为主的企业。企业注册资本8000万人民币，实缴资本5584.26万人民币。公司法定代表人为邓勇。 资金流向方面，今日主力资金净流出2051.53万元，占比成交额16.45%。其中，超大单净流出435.00万 元、占成交额3.49%，大单净流出1616.53万元、占成交额12.96%，中单净流出流入860.80万元、占成交 额6.9%，小单净流入1190.73万元、占成交额9.55%。 金融界消息 截至2025年8月11日收盘，多瑞医药（301075）报收于35.7元，下跌1.76%，换手率4.33%， 成交量3.47万手，成交金额1.25亿元。 多瑞医药最新一期业绩显示，截至2025一季报，公司营业总收入4944.34万元、同比减少36.98%，归属 净利润1559.82万元，同比减少514.76%，扣非净利润1700.81万元，同比减少353.64%，流动比率1.290、 速动比率1.169、资产负债率52.00%。 通过天眼查大数据分析，西藏多瑞医药股份有限公司共对外投资了20家企业，参与招投标项目9次，知 ...

Core Viewpoint - Duori Pharmaceutical is primarily focused on collaborative research and development of innovative drugs, with a promising market outlook for its product Yilung Jisheng Granules, which has completed Phase II clinical trial enrollment as of the end of December 2024 [1] Group 1 - The company has reported that the research and development progress of Yilung Jisheng Granules is proceeding smoothly [1] - The specific timeline for the product's market launch remains uncertain, and the company will fulfill its information disclosure obligations in accordance with relevant regulations [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) is primarily focused on collaborative research and development of innovative drugs, with promising market prospects for its drug candidate Yilung Jisheng Granules, which has completed Phase II clinical trial enrollment as of the end of December 2024 [1] Summary by Relevant Categories Company Development - The company has reported that the Yilung Jisheng Granules have made steady progress in research and development [1] - The specific timeline for the drug's market launch remains uncertain, and the company will fulfill its information disclosure obligations in accordance with relevant regulations [1] Industry Outlook - The market potential for Yilung Jisheng Granules is considered broad, indicating a positive outlook for the company's innovative drug pipeline [1]

Group 1 - The core viewpoint of the article is that the company primarily focuses on collaborative research and development for its innovative drugs, with a specific mention of the Yilung Jisheng Granules currently in clinical trials [1] - As of the end of December 2024, the Yilung Jisheng Granules have completed the enrollment of Phase II clinical trial cases, indicating positive progress in the drug's development [1] - The market outlook for Yilung Jisheng Granules is described as broad, suggesting potential for significant market opportunities once the drug is launched [1]

天眼查商业履历信息显示，西藏多瑞医药股份有限公司，成立于2016年，位于昌都市，是一家以从事批 发业为主的企业。企业注册资本8000万人民币，实缴资本5584.26万人民币。公司法定代表人为邓勇。 通过天眼查大数据分析，西藏多瑞医药股份有限公司共对外投资了20家企业，参与招投标项目9次，知 识产权方面有商标信息60条，专利信息15条，此外企业还拥有行政许可27个。 来源：金融界 金融界消息 截至2025年7月30日收盘，多瑞医药（301075）报收于38.6元，上涨8.43%，换手率 14.43%，成交量11.55万手，成交金额4.53亿元。 资金流向方面，今日主力资金净流出2557.83万元，占比成交额5.64%。其中，超大单净流入626.07万 元、占成交额1.38%，大单净流出3183.90万元、占成交额7.02%，中单净流出流入1603.14万元、占成交 额3.54%，小单净流入954.69万元、占成交额2.11%。 多瑞医药最新一期业绩显示，截至2025一季报，公司营业总收入4944.34万元、同比减少36.98%，归属 净利润1559.82万元，同比减少514.76%，扣非净利润1700.81万元 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-063 西藏多瑞医药股份有限公司 | 序 | 购买 | 受托方名称 | 产品名称 | 金额 | 产品 | 产品起息 | 产品 | 预期年化 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 主体 | | | （万元） | 类型 | 日 | 到期日 | 收益率 | | 1 | 湖北多瑞药 | 中信证券股 | 安泰回报系列 | 2,000 | 浮动收益型 | 2025/7/17 | 2025/10/16 | 1.0000%- | | | 业有限公司 | 份有限公司 | 1411 期收益凭证 | | 收益凭证 | | | 4.1400% | 注：上述金额未扣除交易费用，下同。 三、 关联关系说明 公司与上述委托理财的受托方不存在关联关系，公司本次进行现 金管理不涉及关联交易。 四、 投资风险分析及风险控制措施 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗 ...